A funder-based comparison of global oncology research led by NCI-designated cancer centers: Results from the 2021 global oncology survey

e18535 Background: Equitable global cancer research partnerships are key to reducing the global burden of cancer, which disproportionately affects low-and middle-income countries (LMICs). One indicator of equitable partnerships is the inclusion of LMIC investigators in global cancer research. In 2021 the National Cancer Institute (NCI) conducted a survey of the 71 NCI-Designated Cancer Centers about their global oncology activity. The survey results highlight cancer centers' non-NIH funded global cancer research, training, and capacity-building projects and complement data about global cancer research funded by the National Institutes of Health (NIH). This analysis presents NIH and non-NIH funded global oncology research led by cancer centers stratified by collaborator income class. Methods: NCI designed and fielded an online survey to cancer center global oncology contacts and principal investigators of research projects from July 2021 through January 2022. Data about NIH grants were sourced from internal NIH systems. Income classes are defined by the World Bank and analysis was conducted in Microsoft Excel and Python. A two proportion Z test was used to test for differences in collaborator income class between NIH grants and non-NIH funded projects. Results: Ninety-four percent (67/71) of cancer centers responded to the survey. Forty-seven cancer centers reported 257 global oncology projects with named international collaborating institutions in 2021. Comparatively, 69 cancer centers held 688 NIH cancer research grants with international collaborating institutions in 2021. These projects and grants had collaborators in 111 countries, including 72 LMICs. Projects and grants were stratified by whether they had collaborators only in high-income countries (HICs), only in LMICs, or in both HICs and LMICs, as shown in Table 1. Non-NIH funded global oncology projects were significantly more likely than NIH grants to have only LMIC collaborators (p = 0.0006) or both HIC and LMIC collaborators (p < 0.0001). Conclusions: While the inclusion of LMIC collaborators in research does not guarantee an equitable partnership nor effective research, it is one indicator of these efforts. The results of the global oncology survey demonstrate that cancer centers are committed to conducting research in LMICs and with LMIC institutions, and they are more likely to collaborate with LMIC institutions when supported by a non-NIH funder or by institutional funds. Further analysis is recommended to understand the extent to which research collaboration indicates equitable partnership, and the barriers and facilitators to collaboration posed by different funding sources. [Table: see text]